07.01.2026 • News

Mike Radossich Assumes Role of Syensqo CEO

Seasoned Syensqo business leader to guide the company’s next chapter.

Mike Radossich
Mike Radossich, CEO, Syensqo
© Syensqo

Syensqo recently announced that, further to the announcement made last fall, Mike Radossich has officially assumed the role of Chief Executive Officer and member of the Board of Directors. Mike succeeds Ilham Kadri, who will continue supporting the company as a special advisor to ensure a smooth transition of leadership. These changes are effective from January 1, 2026.

A long-standing Syensqo executive with extensive experience leading global businesses, Mike brings deep industry knowledge and a strong track record of operational excellence. He will steer Syensqo’s next phase as the company continues to focus on creating value for its stakeholders, accelerating sustainable, profitable growth, and driving long-term performance.

Company

Logo:

Syensqo

rue de la Fusée 98
B-1130 Brussels
Belgium

Company contact







Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

most read